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Background: Early descriptions of the coronavirus outbreak showed a lower prevalence of 
asthma and COPD than was expected for people diagnosed with COVID-19, leading to 
speculation that inhaled corticosteroids (ICS) may protect against infection with SARS-CoV-
2, and development of serious sequelae. We evaluated the association between ICS and 
COVID-19 related death using linked electronic health records in the UK.    
Methods: We conducted cohort studies on two groups of people (COPD and asthma) using 
the OpenSAFELY platform to analyse data from primary care practices linked to national 
death registrations. People receiving an ICS were compared to those receiving alternative 
respiratory medications. Our primary outcome was COVID-19 related death. 
Findings: We identified 148,588 people with COPD and 817,973 people with asthma 
receiving relevant respiratory medications in the four months prior to 01 March 2020. People 
with COPD receiving ICS were at a greater risk of COVID-19 related death compared to 
those receiving a long-acting beta agonist (LABA) and a long-acting muscarinic antagonist 
(LAMA) (adjusted HR = 1.38, 95% CI = 1.08 – 1.75). People with asthma receiving high 
dose ICS were at an increased risk of death compared to those receiving a short-acting beta 
agonist (SABA) only (adjusted HR = 1.52, 95%CI = 1.08 – 2.14); the adjusted HR for those 
receiving low-medium dose ICS was 1.10 (95% CI = 0.82 – 1.49). Quantitative bias analyses 
indicated that an unmeasured confounder of only moderate strength of association with 
exposure and outcome could explain the observed associations in both populations.   
Interpretation: These results do not support a major role of ICS in protecting against 
COVID-19 related deaths. Observed increased risks of COVID-19 related death among 
people with COPD and asthma receiving ICS can be plausibly explained by unmeasured 
confounding due to disease severity.  
 
Funding: This work was supported by the Medical Research Council MR/V015737/1. 
 




The ongoing pandemic due to the novel coronavirus, SARS-CoV-2, has now affected over 7 
million people worldwide with at least 400,000 people having died with COVID-191. People 
with more severe COVID-19 outcomes, including hospitalisation or death, tend to be older 
and have pre-existing comorbidities 2,3,4,5,6,7,8.  Severe outcomes are often a result of lung 
complications, such as acute respiratory distress syndrome (ARDS) and respiratory failure. 
However, early reports of COVID-19 patients described an unexpectedly low prevalence of 
chronic respiratory conditions among hospitalised patients9. Although other studies suggest 
that chronic lung diseases, including chronic obstructive pulmonary disease (COPD), 
increase the risk of severe outcomes6–8, reported effect sizes for asthma have been modest 
6,7. This has led to speculation that treatments for respiratory disease, specifically inhaled 
corticosteroids (ICS), may have a protective effect against SARS-CoV-2.9–11.  
 
ICS are used to reduce airway inflammation, oedema, and mucus secretions. In-vitro 
evidence indicates that the ICS ciclesonide can suppress SARS-CoV-2 replication12, and 
budesonide combined with glycopyrronium and formoterol inhibits the production of 
cytokines in cells exposed to HCoV-229E, another human coronavirus13. The oral/IV steroid 
dexamethasone has recently been shown to reduce the risk of death in severe COVID-1914. 
Conversely, although ICS have low systemic absorption, they have been associated with 
increased risk of developing pneumonia in people with COPD 15–17, as well as other systemic 
steroid-related adverse effects18. A recent systematic review of the role of ICS in SARS-
CoV-2, SARS-CoV-1, and MERS found no studies investigating the impact of prior ICS use 
on outcomes in any of these infections 10. 
 
We therefore set out to explore the association between current ICS use and outcomes in 
COVID-19, using the OpenSAFELY platform which contains linked primary care electronic 










Study Design  
We conducted two cohort studies using primary care electronic health record (EHR) data 
linked to death data from the Office for National Statistics (ONS). The index date (start of 
follow up) for both cohorts was 01 Mar 2020; follow-up lasted until 06 May 2020. 
 
Data Source 
Primary care records managed by the GP software provider The Phoenix Partnership (TPP) 
were linked to ONS death data through OpenSAFELY, a data analytics platform created by 
our team on behalf of NHS England19 to address urgent COVID-19 research questions 7 
(https://opensafely.org). OpenSAFELY provides a secure software interface allowing the 
analysis of pseudonymised primary care patient records from England in near real-time 
within the EHR vendor’s highly secure data centre, avoiding the need for large volumes of 
potentially disclosive pseudonymised patient data to be transferred off-site. This, in addition 
to other technical and organisational controls, minimises the risk of re-identification. Similarly 
pseudonymised datasets from other data providers are securely provided to the EHR vendor 
and linked to the primary care data. The dataset analysed within OpenSAFELY is based on 
24 million people currently registered with GP surgeries using TPP SystmOne software. It 
includes pseudonymised data such as coded diagnoses, medications and physiological 
parameters. No free text data is included. 
 
Study Populations 
The COPD cohort included adults older than 35 years with COPD and current or former 
smoking recorded any time before the index date20. We excluded people with prior 
diagnoses of other chronic respiratory conditions, or with asthma in the three years before 
the index date21, and those receiving nebulised COPD medications in the twelve months 
before the index date or a leukotriene receptor antagonist (indicating potential asthma) in the 
four months before the index date.  
 
The asthma cohort included adults older than 18 years with asthma recorded within three 
years prior to the index date. People with COPD or other chronic respiratory conditions prior 
to the index date were excluded, as were those receiving a LAMA without an ICS, as this 
indicates possible COPD22.  
  
People with missing data for gender, index of multiple deprivation (IMD), or less than one 
year of primary care records were excluded (supplemental figure 1).  
 
Exposures 
In the COPD population, people issued at least one ICS prescription within four months prior 
to the index date either in combination with LABA or LAMA/LABA, or as single therapy 
provided there was also at least one prescription record of a LABA,  were compared with 
those with a prescription for a LABA/LAMA (combined or as separate single therapy 
prescriptions) only22. We did not include patients receiving LAMA monotherapy, as we were 
expecting greater clinical comparability between the LAMA/LABA and ICS-based therapy 
groups. 
 
In the asthma population, people prescribed high dose ICS and low/medium-dose ICS 
during the four months before index date were compared with those prescribed SABA only. 
Exposure for people prescribed both high and low/medium dose ICS was assigned 
according to their most recent prescription. Inhalers were assigned to low/medium or high 
dose based the OpenPrescribing.net prescribing explorer which was developed based on 
BTS/SIGN guidance23 . Studies have shown that a significant percentage of people with 
asthma receiving SABA only are eligible for ICS treatment24, suggesting they have similar 
disease severity to those receiving ICS and therefore represent a reasonable comparator 
group. The characteristics of all other people are described in supplementary material 
(supplemental table 1-2), however they are excluded from regression models to avoid 
comparisons to individuals not prescribed drugs of interest 25.  
 
Outcomes 
The outcome was COVID-19 related death as registered in ONS data using ICD-10 codes 
U07.1 (“COVID-19, virus identified”) and U07.2 ( “COVID-19, virus not identified”) listed 
either as the underlying or any contributing cause of death. The latter ICD-10 code is used 
when laboratory testing is inconclusive or unavailable26. 
 
Covariates 
Potential determinants of exposures and outcomes were identified by reviewing literature 
and through discussions with practising clinicians. As this is a study of current users, 
determinants of exposures include both factors that may affect the initial choice of treatment 
as well as those that influence whether patients remain on a certain treatment. The final list 
of potential confounders can be seen in box 1. Our methodology for creating codelists 
associated with these confounders has been previously described7: this included clinical and 
epidemiological review and sign-off by at least two authors. Detailed information on every 
codelist is shared at https://codelists.opensafely.org/. 
Statistical Methods  
Individuals characteristics were summarised using descriptive statistics, stratified by 
exposure status. Time to the primary outcome is displayed in Kaplan-Meier (KM) plots with 
time in study as the timescale. The competing risk of death from non-COVID-19 causes was 
dealt with by analysing the cause-specific hazard, with people dying from other causes 
censored at their date of death27. We used cause-specific Cox regression models to estimate 
hazard ratios (HRs) and 95% confidence intervals (CIs) for the association between 
exposure categories and the outcome in each population. Univariable models, models 
adjusted for age (using restricted cubic splines) and sex as well as fully adjusted models 
including all covariates were fitted. Region was included as a stratification variable in fully 
adjusted models. We evaluated an a priori specified interaction between ICS exposure and 
age, to see if we could distinguish a differential effect in groups known to be at higher risk. 
Sensitivity Analyses 
In sensitivity analyses, first, we split the exposure categories in the COPD population to 
examine the effect of ICS with LABA/LAMA (triple combination) and ICS with LABA (dual 
combination) separately, anticipating greater underlying disease severity in people receiving 
triple therapy. Second, we restricted analyses to the largest ethnicity group (i.e., white 
British) to exclude any substantial confounding by ethnicity. We did not adjust for ethnicity in 
the main models as this was not anticipated to be a strong confounder and due to a sizable 
proportion of individuals with missing ethnicity (~25%). In the asthma population, we varied 
the sample definition to include people with asthma diagnosed at any time, and a recent 
prescription for any asthma medication.  
 
Negative Control Outcomes  
We hypothesised that disease severity, but not ICS use, may influence the risk of non-
COVID-19 related death. Analyses were therefore conducted using non-COVID-19 death as 
a negative control outcome censoring people at time of COVID-19 related death. If any 
potentially harmful association observed in primary analyses was due to confounding (i.e. 
people prescribed ICS had more severe underlying respiratory disease than those who did 
not) we expected to observe a similar association with non-COVID-19 related death in 
people prescribed ICS. 
Quantitative Bias Analysis  
We used e-value formulae to calculate the minimum strengths of association between an 
unmeasured confounder and exposure or outcome, conditional on measured covariates, 
necessary to fully explain observed associations28.  
Software and Reproducibility 
Data management was performed using Python 3.8 and SQL, with analysis carried out using 
Stata 16.1. All of the code used for data management and analyses is openly shared online 
for review and re-use (https://github.com/opensafely/ics-research). All iterations of the pre-
specified study protocol are archived with version control (https://github.com/opensafely/ics-
research/tree/master/protocol).  
 
Patient and Public Involvement 
Patients were not formally involved in developing this specific study design that was 
developed rapidly in the context of a global health emergency. We have developed a publicly 
available website https://opensafely.org/ through which we invite any patient or member of 
the public to contact us regarding this study or the broader OpenSAFELY project. The 
protocol and draft paper have been sent to the Asthma UK and British Lung Foundation 






Patient Characteristics  
148,488 people with COPD and 817,973 people with asthma and a relevant prescription 
within the four months before 01 Mar 2020 were included (supplemental figure 2-3).  
COPD Population 
Table 1 (see end) shows the characteristics of the COPD population. 43,278 (29%) received 
a LABA/LAMA prescription in the 4 months before index, and 105,210 (71%) prescriptions 
for ICS+LABA or ICS+LABA/LAMA. Demographic characteristics of treatment groups were 
similar; median age was 71 (IQR = 63 - 77) in the LABA/LAMA group and 72 (IQR = 64 - 78) 
in the ICS group, and just over half were men (54.5% in the LABA/LAMA group and 53.7% in 
the ICS group).  
 
The presence of comorbidities was similar across the two treatment groups, except prior 
asthma diagnosis, which was more common among ICS recipients (12.9% in the 
LABA/LAMA group compared to 27.7% in the ICS group). The percentage of people with an 
exacerbation in the last year was lower in the LABA/LAMA group (19.7% vs 26.0%).  
 
Asthma Population   
Table 2 (see end) shows the characteristics of the asthma population. Most (608,583, 74%) 
had a prescription for low/medium dose ICS in the four months prior to index date; fewer 
received high dose ICS (101,010, 12%) and SABA only (108,380, 13%).  
 
The asthma treatment groups differed in terms of demographic and clinical characteristics. 
The median age was 48 (IQR = 35 - 60), 53 (IQR = 40 - 66), and 55 (IQR = 44 - 67) for 
SABA only, low/medium dose ICS and high dose ICS respectively. The proportion of men 
was highest in the SABA group (43.0%), followed by the low/medium dose ICS (40.3%) and 
high dose ICS (38.2%).  
 
The prevalence of most comorbidities was lowest among people in the SABA only group and 
highest in the high dose ICS group. The proportion with an asthma exacerbation in the past 
year increased markedly across treatment groups (14.0%, 20.0% and 36.3% among SABA, 
low/medium dose and high dose ICS respectively). 
Univariable and Multivariable Results  
COPD 
421 COVID-19 related deaths occurred in the treated COPD population; time to COVID-19 
related death by treatment group can be seen in Figure 1a. In univariable models, ICS use 
was associated with an increased risk of COVID-19 related death (HR = 1.52, 95% CI = 1.20 
- 1.91; Figure 2). This association decreased on adjustment for age and gender, and the 
remaining comorbidities (aHR = 1.38; 95% CI = 1.08 - 1.75; Figure 2). Post-hoc analyses 
revealed that adjustment for prior exacerbations as a binary variable and smoking status 
(current/former) had the largest impact on reducing the hazard ratio (supplemental table 6). 
There was no evidence of a (pre-specified) interaction with age (supplemental table 4). We 
detected significant deviations from the proportional hazards assumptions by testing for a 
zero slope in the scaled Schoenfeld residuals as well as by graphical inspection of plots of 
the Schoenfeld residuals against time (supplemental table 5, figure 4-6). The KM curve 
indicated that the hazard ratio was likely above one throughout the follow-up, with the effect 
size growing over time.  
 




There were 515 COVID-19 related deaths in the treated asthma population; time to COVID-
19 related death by treatment group can be seen in Figure 1b. In univariable models, receipt 
of both low/medium dose and high dose ICS was associated with an increased risk of 
COVID-19 related death (HR = 1.32, 95% CI = 0.98 - 1.77 and HR = 2.28, 1.62 - 3.20 
respectively; Figure 3). These associations reduced markedly upon adjustment for age and 
gender, and the remaining pre-specified comorbidities (aHR = 1.10, 95% CI = 0.82 - 1.49 
and aHR = 1.52, 95% CI = 1.08 - 2.14 for low/medium dose and high dose ICS respectively; 
Figure 3). Post-hoc analyses revealed that the greatest reduction in the strength of the 
association after the age and sex adjustment was adjustment for previous exacerbations 
(supplemental table 10). There was no evidence for a (pre-specified) interaction with age , 
and no deviations from the proportional hazards assumption (supplemental table 8 and 9, 







Figure1b: Kaplan-Meier plots in in the asthma population 
 
Sensitivity Analyses 
Figure 2 and 3 show results from sensitivity analyses. When considering receipt of ICS + 
LABA and ICS + LABA/LAMA separately in the COPD population, the risk of death was 
higher among those receiving ICS + LABA/LAMA (aHR = 1.41 95% CI = 1.10 - 1.81) but 
less markedly amongst those receiving ICS + LABA (aHR = 1.29, 95% CI = 0.95 - 1.74). 
Restricting analyses to people of white ethnicity to attempt to control for potential 
confounding by ethnicity led to a reduction in the hazard ratios in the COPD population 
(Figure 2), but not in the asthma population (Figure 3). Changing the population 

















Figure 2: Univariable and Multivariable Models, COPD population 
Figure 3: Univariable and Multivariable Models, Asthma population
 
Negative Control Analysis 
In the COPD population, the risk of non-COVID-19 related death was higher among 
individuals in the ICS combination group with an adjusted HR = 1.23 (95% CI = 1.07 - 1.40). 
In the asthma population, there was no evidence of an association between receipt of high 
or low/medium dose ICS and non-COVID-19 related death with adjusted HRs of 0.85 (95% 
CI = 0.71 - 1.00) and 0.93 (95% CI = 0.75 - 1.15), respectively. 
Quantitative Bias Analysis  
To fully explain the lower bound of the 95% CI in the COPD cohort (1.08), or for the high-
dose ICS association in the asthma cohort (1.08), an unmeasured confounder would need to 
be associated (conditional on measured covariates) with either exposure or outcome by at 
least risk ratio (RR) 1.37 (e-value/high threshold) and with both exposure and outcome by at 
least RR 1.08 (low threshold; Figure 4a-b). An unmeasured confounder would need to have 
a stronger association with either exposure or outcome to move the observed HRs to a 
clinically meaningful protective effect of 0.8 (high threshold COPD: 2.84, asthma: 3.21, 
supplemental figure 14-15; low threshold COPD: 1.73, asthma: 1.90).  
Figure 4a: E-value for the lower 95% CI and point estimate in the COPD  
 







This is the first study to investigate the association between regular ICS use and COVID-19 
related death. Compared with non-ICS based treatments, ICS in people with COPD was 
associated with a ~40% increased risk of COVID-19 related death. In people with asthma, 
high dose ICS use was associated with an ~50% increased risk of COVID-19 related death, 
with little evidence of any association for low/medium dose ICS. Our findings do not provide 
any strong support for a protective effect from ICS use in these populations, as has been 
previously hypothesised. Our analyses overall indicate that the observed harmful 
associations could readily be explained by confounding due to underlying health differences 
between people prescribed ICS and those using other medications for asthma and COPD, 
rather than a causally harmful effect of ICS. Specifically, we observed a stronger association 
with COVID-19 related death between ICS triple therapy than ICS dual therapy in the COPD 
cohort; the ICS content of these two regimens is similar, and a causal effect of ICS would be 
expected to be comparable in these two groups. If we had successfully controlled for 
disease severity differences between treatment groups, we would also expect to see no 
association between ICS and the negative control outcome of non-COVID-19 death. The 
harmful association we observed suggests we had not perfectly captured all markers of 
disease severity, resulting in an association that is unlikely to be causal. The null finding 
between ICS and non-COVID-19 related death in the asthma cohort is less surprising, since 
asthma is less markedly associated with overall mortality compared to COPD29. Finally, 
quantitative bias analysis confirms that a hypothetical unmeasured confounder of modest 
strength could fully explain the observed results.  
 
Findings in Context 
A literature review (box 2) found no other epidemiological studies or randomised controlled 
trials (RCTs) assessing the role of ICS in COVID-19. Two ongoing RCTs investigating the 
role of ICS in people hospitalised with laboratory confirmed COVID-19 and mild COVID-19 
respectively (NCT04331054, NCT04330586) are due to complete later this year. The 
hypothesis of a protective effect of ICS in COVID-19 was based partly on the prevalence of 
chronic lung disease among outpatient and inpatient COVID-19 in China. However, more 
recent studies do not support initial assertions that people with chronic lung diseases 
(including COPD) are significantly underrepresented among COVID-19 patients 6,7,30. In 
addition, a number of studies have found that people with COPD are at greater risk of severe 
COVID-19 and death from COVID-19 once infected 6,7. The evidence for asthma in COVID-
19 is more varied, with studies reporting both null and moderately harmful associations6,7. It 
may be that features other than ICS use, such as shielding, influence the risk of acquiring 
SARS-CoV-2 among asthmatics. Studies investigating the causal effect of chronic 
respiratory disease, including COPD, and asthma on SARS-CoV-2 infection risk and COVID-
19 disease, ideally taking into account the relatively large degree of heterogeneity that exists 
within each of these diagnostic categories, are urgently needed to help inform about levels of 
risk for these patients.  
 
Strengths and weaknesses 
The greatest strength of this study was the power we had to look at multiple drug treatments 
as our dataset included medical records from almost 24 million individuals. Our study is 
further strengthened by the use of two different study populations and active comparators, 
as well as sensitivity analyses to quantify the potential impact of unmeasured confounding 
on results. Another strength is our use of open methods: we pre-specified our analysis plan 
and have shared all analytical code.  
 
We also recognise possible limitations. The primary limitation is the risk of confounding by 
indication due to unmeasured or imperfectly defined potential confounding variables.  
Decisions regarding treatment choices involve factors that may not be well recorded in 
electronic health records including measures such as spirometry, and likely steroid 
responsiveness. As we did not have secondary care data our assessment of exacerbation 
history was incomplete, limiting our ability to adjust for this. Our sensitivity analyses confirm 
that unmeasured confounding is a plausible reason for the harmful associations we 
observed. The proportional hazards assumption was not met for the COPD models, with KM 
plots indicating that the hazard ratio for this exposure increased over time. This is perhaps 
not surprising, as the risk of acquiring COVID-19 was lower in the early stages of the 
pandemic. The HR for the COPD population should be interpreted as an average over the 
entire follow-up period. Finally, it is important to note that the outcome of COVID-19 related 
death will reflect the risk both of becoming infected as well as the risk of developing severe 
disease and dying. It is possible that ICS use has a different effect on the risk of infection 
and on disease severity.  
 
Policy Implications and Future Research 
We find no evidence that ICS has a strongly beneficial effect on COVID-19 related mortality, 
and therefore we cannot recommend that they are used to treat people with COVID-19 
outside of the context of RCTs. Importantly, from the totality of the evidence provided here, 
including our sensitivity analyses, our results do not support the interpretation that regular 
ICS therapy for asthma or COPD increases risk of death from COVID-19, and do not provide 
evidence to support adjustments in ICS therapy among COVID-19 patients. Future 
observational studies of this clinical question are likely to face similar challenges around 
unmeasured confounding. 
 
The UK has an unusually large volume of detailed longitudinal patient data. We have 
demonstrated that it is feasible to rapidly address specific hypotheses about medicines in a 
transparent manner inside the secure environment of an EHR vendor in order to minimise 
the large volumes of potentially disclosive data that would otherwise have to move into 
separate systems. We will use the OpenSAFELY platform to further inform the global 
response about drug treatments during the COVID-19 emergency.   
 
Summary 
We found no evidence of a beneficial effect of regular ICS use on COVID-19 related 
mortality. Although we report a small harmful association, the pattern of results we observed 
suggests this could readily be explained by differences in underlying health between people 
receiving ICS and those receiving other respiratory medications. People currently taking ICS 




















Table 1. Demographic and Clinical Characteristics - COPD 
    Total LABA/LAMA Combination ICS Combination Other 
Total Included    291,805 (100.0)    43,278 (100.0)   105,210 (100.0)   143,317 (100.0) 
Demographics       
Grouped age 18 - <40     1,232 (0.4)        85 (0.2)       184 (0.2)       963 (0.7) 
  40 - <50    10,028 (3.4)     1,060 (2.4)     2,289 (2.2)     6,679 (4.7) 
  50 - < 60     40,910 (14.0)     5,746 (13.3)    12,237 (11.6)    22,927 (16.0) 
  60 - <70     80,788 (27.7)    12,599 (29.1)    29,519 (28.1)    38,670 (27.0) 
  70 - <80    104,319 (35.7)    16,092 (37.2)    40,370 (38.4)    47,857 (33.4) 
  80+    54,528 (18.7)     7,696 (17.8)    20,611 (19.6)    26,221 (18.3) 
        
Age (years) Median (IQR) 71 (63-77) 71 (63-77) 72 (64-78) 70 (61-77) 
  Mean (SD) 69.76 (10.76) 70.03 (10.10) 70.76 (10.10) 68.95 (11.38) 
  Min, Max 35, 103 35, 100 35, 102 35, 103 
        
Male No   133,738 (45.8)    19,699 (45.5)    48,707 (46.3)    65,332 (45.6) 
  Yes   158,067 (54.2)    23,579 (54.5)    56,503 (53.7)    77,985 (54.4) 
        
Grouped BMI Underweight (<18.5)    11,359 (3.9)     1,682 (3.9)     4,744 (4.5)     4,933 (3.4) 
  Normal (18.5-24.9)    89,195 (30.6)    12,938 (29.9)    31,858 (30.3)    44,399 (31.0) 
  Overweight (25-29.9)     95,443 (32.7)    14,011 (32.4)    33,494 (31.8)    47,938 (33.4) 
  Obese I (30-34.9)    55,541 (19.0)     8,590 (19.8)    20,278 (19.3)    26,673 (18.6) 
  Obese II (35-39.9)    22,054 (7.6)     3,568 (8.2)     8,379 (8.0)    10,107 (7.1) 
  Obese III (40+)    10,006 (3.4)     1,580 (3.7)     3,945 (3.7)     4,481 (3.1) 
  Missing     8,207 (2.8)       909 (2.1)     2,512 (2.4)     4,786 (3.3) 
        
Smoking status Never         0 (0.0)         0 (0.0)         0 (0.0)         0 (0.0) 
  Former   184,400 (63.2)    26,015 (60.1)    69,710 (66.3)    88,675 (61.9) 
  Current    107,405 (36.8)    17,263 (39.9)    35,500 (33.7)    54,642 (38.1) 
  Missing         0 (0.0)         0 (0.0)         0 (0.0)         0 (0.0) 
        
Ethnicity White   218,717 (75.0)    32,455 (75.0)    79,682 (75.7)   106,580 (74.4) 
  Mixed       676 (0.2)        92 (0.2)       186 (0.2)       398 (0.3) 
  Asian or Asian British     3,366 (1.2)       258 (0.6)       835 (0.8)     2,273 (1.6) 
  Black     1,208 (0.4)       103 (0.2)       302 (0.3)       803 (0.6) 
  Other      1,060 (0.4)       113 (0.3)       286 (0.3)       661 (0.5) 
  Unknown     66,778 (22.9)    10,257 (23.7)    23,919 (22.7)    32,602 (22.7) 
        
Index of Multiple 
Deprivation (IMD) Least Deprived    58,902 (20.2)     8,049 (18.6)    19,893 (18.9)    30,960 (21.6) 
  2    58,779 (20.1)     8,419 (19.5)    20,619 (19.6)    29,741 (20.8) 
  3    59,175 (20.3)     8,755 (20.2)    21,235 (20.2)    29,185 (20.4) 
  4    57,633 (19.8)     8,431 (19.5)    21,634 (20.6)    27,568 (19.2) 
  Most Deprived    57,316 (19.6)     9,624 (22.2)    21,829 (20.7)    25,863 (18.0) 
  Missing         0 (0.0)         0 (0.0)         0 (0.0)         0 (0.0) 
Treatments        
Single SABA No   125,025 (42.8)    12,349 (28.5)    21,544 (20.5)    91,132 (63.6) 
  Yes   166,780 (57.2)    30,929 (71.5)    83,666 (79.5)    52,185 (36.4) 
        
High Dose ICS No   266,112 (91.2)    43,278 (100.0)    79,748 (75.8)   143,086 (99.8) 
  Yes    25,693 (8.8)         0 (0.0)    25,462 (24.2)       231 (0.2) 
        
Low/Medium Dose 
ICS No   204,577 (70.1)    43,278 (100.0)    22,739 (21.6)   138,560 (96.7) 
  Yes    87,228 (29.9)         0 (0.0)    82,471 (78.4)     4,757 (3.3) 
        
Single ICS No   284,499 (97.5)    43,278 (100.0)   102,887 (97.8)   138,334 (96.5) 
  Yes     7,306 (2.5)         0 (0.0)     2,323 (2.2)     4,983 (3.5) 
        
Single SAMA No   288,487 (98.9)    43,120 (99.6)   103,725 (98.6)   141,642 (98.8) 
  Yes     3,318 (1.1)       158 (0.4)     1,485 (1.4)     1,675 (1.2) 
        
Single LABA No   283,744 (97.2)    40,849 (94.4)   104,356 (99.2)   138,539 (96.7) 
  Yes     8,061 (2.8)     2,429 (5.6)       854 (0.8)     4,778 (3.3) 
        
Single LAMA No   204,171 (70.0)    38,690 (89.4)    59,736 (56.8)   105,745 (73.8) 
  Yes    87,634 (30.0)     4,588 (10.6)    45,474 (43.2)    37,572 (26.2) 
        
LABA ICS No   216,279 (74.1)    43,278 (100.0)    29,684 (28.2)   143,317 (100.0) 
  Yes    75,526 (25.9)         0 (0.0)    75,526 (71.8)         0 (0.0) 
        
LABA LAMA No   245,652 (84.2)     1,929 (4.5)   100,406 (95.4)   143,317 (100.0) 
  Yes    46,153 (15.8)    41,349 (95.5)     4,804 (4.6)         0 (0.0) 
        
LABA LAMA ICS No   258,774 (88.7)    43,278 (100.0)    72,179 (68.6)   143,317 (100.0) 
  Yes    33,031 (11.3)         0 (0.0)    33,031 (31.4)         0 (0.0) 
        
Single LTRA No   291,805 (100.0)    43,278 (100.0)   105,210 (100.0)   143,317 (100.0) 
  Yes         0 (0.0)         0 (0.0)         0 (0.0)         0 (0.0) 
        
Clinical Conditions      
Chronic kidney 
disease No   241,927 (82.9)    35,547 (82.1)    86,857 (82.6)   119,523 (83.4) 
  Yes    49,878 (17.1)     7,731 (17.9)    18,353 (17.4)    23,794 (16.6) 
        
Diagnosed 
hypertension No   146,895 (50.3)    21,595 (49.9)    50,961 (48.4)    74,339 (51.9) 
  Yes   144,910 (49.7)    21,683 (50.1)    54,249 (51.6)    68,978 (48.1) 
        
Heart Failure No   267,221 (91.6)    39,424 (91.1)    95,255 (90.5)   132,542 (92.5) 
  Yes    24,584 (8.4)     3,854 (8.9)     9,955 (9.5)    10,775 (7.5) 
        
Other Heart 
Diseases No   226,356 (77.6)    33,233 (76.8)    81,114 (77.1)   112,009 (78.2) 
  Yes    65,449 (22.4)    10,045 (23.2)    24,096 (22.9)    31,308 (21.8) 
        
Cancer No   251,789 (86.3)    37,060 (85.6)    90,144 (85.7)   124,585 (86.9) 
  Yes    40,016 (13.7)     6,218 (14.4)    15,066 (14.3)    18,732 (13.1) 
Diabetes Severity       
  No Diabetes   221,197 (75.8)    32,888 (76.0)    79,531 (75.6)   108,778 (75.9) 
  Diabetes, not severe    51,265 (17.6)     7,583 (17.5)    19,011 (18.1)    24,671 (17.2) 
  Diabetes, severe    18,561 (6.4)     2,711 (6.3)     6,363 (6.0)     9,487 (6.6) 
  Diabetes, no Hb1AC       782 (0.3)        96 (0.2)       305 (0.3)       381 (0.3) 
        
Recent Statin No   150,420 (51.5)    20,517 (47.4)    50,894 (48.4)    79,009 (55.1) 
  Yes   141,385 (48.5)    22,761 (52.6)    54,316 (51.6)    64,308 (44.9) 
        
Flu vaccine No    73,828 (25.3)     8,683 (20.1)    19,904 (18.9)    45,241 (31.6) 
  Yes   217,977 (74.7)    34,595 (79.9)    85,306 (81.1)    98,076 (68.4) 
        
Pneumococcal 
Vaccine No   231,323 (79.3)    32,266 (74.6)    83,906 (79.8)   115,151 (80.3) 
  Yes    60,482 (20.7)    11,012 (25.4)    21,304 (20.2)    28,166 (19.7) 
        
Exacerbation in last 
year No   236,123 (80.9)    34,748 (80.3)    77,858 (74.0)   123,517 (86.2) 
  Yes    55,682 (19.1)     8,530 (19.7)    27,352 (26.0)    19,800 (13.8) 
        
Asthma ever No   236,592 (81.1)    37,705 (87.1)    76,033 (72.3)   122,854 (85.7) 
  Yes    55,213 (18.9)     5,573 (12.9)    29,177 (27.7)    20,463 (14.3) 
        
Immunosuppressed 
(combination 
algorithm) No   290,160 (99.4)    43,073 (99.5)   104,672 (99.5)   142,415 (99.4) 
  Yes     1,645 (0.6)       205 (0.5)       538 (0.5)       902 (0.6) 
        
GP consultation 
count Median (IQR) 9 (5-16) 10 (6-16) 10 (6-17) 8 (4-14) 
  Mean (SD) 12.19 (11.62) 12.72 (11.32) 13.43 (12.26) 11.12 (11.12) 
  Min, Max 0, 306 0, 276 0, 306 0, 268 
        
Exacerbation Count Median (IQR) 0 (0-0) 0 (0-0) 0 (0-1) 0 (0-0) 
  Mean (SD) .26 (.63) .26 (.60) .38 (.77) .17 (.48) 
  Min, Max 0, 12 0, 9 0, 12 0, 8 
  
Table 2. Demographic and Clinical Characteristics - Asthma 
 
    Total SABA only 
ICS 
(Low/Medium 
Dose) ICS (High Dose) Other 
Total Included  
  1,285,035 
(100.0)   108,380 (100.0)   608,583 (100.0)   101,010 (100.0)   467,062 (100.0) 
Demographics        
Grouped age 18 - <40   417,254 (32.5)    36,237 (33.4)   144,889 (23.8)    18,816 (18.6)   217,312 (46.5) 
  40 - <50   235,356 (18.3)    22,051 (20.3)   107,786 (17.7)    18,454 (18.3)    87,065 (18.6) 
  50 - < 60    253,115 (19.7)    21,846 (20.2)   130,346 (21.4)    23,742 (23.5)    77,181 (16.5) 
  60 - <70    181,865 (14.2)    13,965 (12.9)   105,828 (17.4)    18,956 (18.8)    43,116 (9.2) 
  70 - <80    130,554 (10.2)     9,206 (8.5)    79,729 (13.1)    13,888 (13.7)    27,731 (5.9) 
  80+    66,891 (5.2)     5,075 (4.7)    40,005 (6.6)     7,154 (7.1)    14,657 (3.1) 
         
Age (years) Median (IQR) 49 (35-62) 48 (35-60) 53 (40-66) 55 (44-67) 41 (29-55) 
  Mean (SD) 49.32 (17.90) 48.32 (17.34) 53.13 (17.37) 55.01 (16.34) 43.36 (17.29) 
  Min, Max 18, 106 18, 106 18, 106 18, 106 18, 105 
         
Male No   750,041 (58.4)    61,799 (57.0)   363,282 (59.7)    62,444 (61.8)   262,516 (56.2) 
  Yes   534,994 (41.6)    46,581 (43.0)   245,301 (40.3)    38,566 (38.2)   204,546 (43.8) 
         
Grouped BMI 
Underweight 
(<18.5)    19,134 (1.5)     1,636 (1.5)     7,618 (1.3)     1,148 (1.1)     8,732 (1.9) 
  Normal (18.5-24.9)   340,536 (26.5)    28,126 (26.0)   152,943 (25.1)    20,937 (20.7)   138,530 (29.7) 
  
Overweight (25-
29.9)    394,590 (30.7)    32,856 (30.3)   196,437 (32.3)    30,752 (30.4)   134,545 (28.8) 
  Obese I (30-34.9)   239,220 (18.6)    20,060 (18.5)   122,118 (20.1)    22,281 (22.1)    74,761 (16.0) 
  Obese II (35-39.9)   112,039 (8.7)     9,494 (8.8)    56,827 (9.3)    11,878 (11.8)    33,840 (7.2) 
  Obese III (40+)    67,768 (5.3)     5,930 (5.5)    34,079 (5.6)     8,243 (8.2)    19,516 (4.2) 
  Missing   111,748 (8.7)    10,278 (9.5)    38,561 (6.3)     5,771 (5.7)    57,138 (12.2) 
         
Smoking status Never   589,698 (45.9)    45,361 (41.9)   268,746 (44.2)    41,200 (40.8)   234,391 (50.2) 
  Former   497,853 (38.7)    42,250 (39.0)   254,169 (41.8)    44,111 (43.7)   157,323 (33.7) 
  Current    195,370 (15.2)    20,611 (19.0)    85,366 (14.0)    15,655 (15.5)    73,738 (15.8) 
  Missing     2,114 (0.2)       158 (0.1)       302 (0.0)        44 (0.0)     1,610 (0.3) 
         
Ethnicity White   882,703 (68.7)    74,312 (68.6)   427,754 (70.3)    71,237 (70.5)   309,400 (66.2) 
  Mixed    12,970 (1.0)       983 (0.9)     5,032 (0.8)       848 (0.8)     6,107 (1.3) 
  
Asian or Asian 
British    72,097 (5.6)     5,693 (5.3)    32,353 (5.3)     5,866 (5.8)    28,185 (6.0) 
  Black    20,495 (1.6)     1,546 (1.4)     8,141 (1.3)     1,453 (1.4)     9,355 (2.0) 
  Other     12,174 (0.9)       895 (0.8)     4,856 (0.8)       876 (0.9)     5,547 (1.2) 
  Unknown    284,596 (22.1)    24,951 (23.0)   130,447 (21.4)    20,730 (20.5)   108,468 (23.2) 
         
Index of Multiple 
Deprivation (IMD) Least Deprived   260,435 (20.3)    21,069 (19.4)   124,381 (20.4)    17,767 (17.6)    97,218 (20.8) 
  2   261,441 (20.3)    21,697 (20.0)   124,199 (20.4)    18,946 (18.8)    96,599 (20.7) 
  3   258,380 (20.1)    21,978 (20.3)   121,807 (20.0)    20,187 (20.0)    94,408 (20.2) 
  4   258,263 (20.1)    22,389 (20.7)   120,992 (19.9)    21,468 (21.3)    93,414 (20.0) 
  Most Deprived   246,516 (19.2)    21,247 (19.6)   117,204 (19.3)    22,642 (22.4)    85,423 (18.3) 
  Missing         0 (0.0)         0 (0.0)         0 (0.0)         0 (0.0)         0 (0.0) 
         
Treatments         
Single SABA No   679,186 (52.9)         0 (0.0)   191,771 (31.5)    22,831 (22.6)   464,584 (99.5) 
  Yes   605,849 (47.1)   108,380 (100.0)   416,812 (68.5)    78,179 (77.4)     2,478 (0.5) 
         
High Dose ICS No   1181109 (91.9)   108,380 (100.0)   605,667 (99.5)         0 (0.0)   467,062 (100.0) 
  Yes   103,926 (8.1)         0 (0.0)     2,916 (0.5)   101,010 (100.0)         0 (0.0) 
         
Low/Medium Dose 
ICS No   668,905 (52.1)   108,380 (100.0)         0 (0.0)    93,463 (92.5)   467,062 (100.0) 
  Yes   616,130 (47.9)         0 (0.0)   608,583 (100.0)     7,547 (7.5)         0 (0.0) 
         
Single ICS No   994,280 (77.4)   108,380 (100.0)   327,894 (53.9)    90,944 (90.0)   467,062 (100.0) 
  Yes   290,755 (22.6)         0 (0.0)   280,689 (46.1)    10,066 (10.0)         0 (0.0) 
         
Single SAMA No   1282214 (99.8)   108,264 (99.9)   606,954 (99.7)   100,113 (99.1)   466,883 (100.0) 
  Yes     2,821 (0.2)       116 (0.1)     1,629 (0.3)       897 (0.9)       179 (0.0) 
         
Single LABA No   1276523 (99.3)   107,837 (99.5)   602,628 (99.0)    99,510 (98.5)   466,548 (99.9) 
  Yes     8,512 (0.7)       543 (0.5)     5,955 (1.0)     1,500 (1.5)       514 (0.1) 
         
Single LAMA No   1268654 (98.7)   108,380 (100.0)   600,539 (98.7)    92,673 (91.7)   467,062 (100.0) 
  Yes    16,381 (1.3)         0 (0.0)     8,044 (1.3)     8,337 (8.3)         0 (0.0) 
         
LABA ICS No   853,659 (66.4)   108,380 (100.0)   270,615 (44.5)     7,602 (7.5)   467,062 (100.0) 
  Yes   431,376 (33.6)         0 (0.0)   337,968 (55.5)    93,408 (92.5)         0 (0.0) 
         
LABA LAMA No   1284675 (100.0)   108,380 (100.0)   608,344 (100.0)   100,889 (99.9)   467,062 (100.0) 
  Yes       360 (0.0)         0 (0.0)       239 (0.0)       121 (0.1)         0 (0.0) 
         
LABA LAMA ICS No   1283765 (99.9)   108,380 (100.0)   607,399 (99.8)   100,924 (99.9)   467,062 (100.0) 
  Yes     1,270 (0.1)         0 (0.0)     1,184 (0.2)        86 (0.1)         0 (0.0) 
         
Single LTRA No   1215202 (94.6)   108,380 (100.0)   568,123 (93.4)    77,972 (77.2)   460,727 (98.6) 
  Yes    69,833 (5.4)         0 (0.0)    40,460 (6.6)    23,038 (22.8)     6,335 (1.4) 
         
Clinical 
Conditions        
Chronic kidney 
disease No   1223801 (95.2)   103,287 (95.3)   573,168 (94.2)    93,958 (93.0)   453,388 (97.1) 
  Yes    61,234 (4.8)     5,093 (4.7)    35,415 (5.8)     7,052 (7.0)    13,674 (2.9) 
         
Diagnosed 
hypertension No   976,993 (76.0)    82,562 (76.2)   432,272 (71.0)    67,177 (66.5)   394,982 (84.6) 
  Yes   308,042 (24.0)    25,818 (23.8)   176,311 (29.0)    33,833 (33.5)    72,080 (15.4) 
         
Heart Failure No   1262657 (98.3)   106,402 (98.2)   596,019 (97.9)    98,019 (97.0)   462,217 (99.0) 
  Yes    22,378 (1.7)     1,978 (1.8)    12,564 (2.1)     2,991 (3.0)     4,845 (1.0) 
         
Other Heart 
Diseases No   1206042 (93.9)   101,496 (93.6)   564,730 (92.8)    91,872 (91.0)   447,944 (95.9) 
  Yes    78,993 (6.1)     6,884 (6.4)    43,853 (7.2)     9,138 (9.0)    19,118 (4.1) 
         
Cancer No   1217695 (94.8)   102,684 (94.7)   571,051 (93.8)    94,267 (93.3)   449,693 (96.3) 
  Yes    67,340 (5.2)     5,696 (5.3)    37,532 (6.2)     6,743 (6.7)    17,369 (3.7) 
Diabetes Severity        
  No Diabetes   1126195 (87.6)    93,542 (86.3)   523,583 (86.0)    83,022 (82.2)   426,048 (91.2) 
  
Diabetes, not 
severe   105,767 (8.2)     8,935 (8.2)    57,791 (9.5)    12,233 (12.1)    26,808 (5.7) 
  Diabetes, severe    48,858 (3.8)     5,545 (5.1)    25,270 (4.2)     5,434 (5.4)    12,609 (2.7) 
  
Diabetes, no 
Hb1AC     4,215 (0.3)       358 (0.3)     1,939 (0.3)       321 (0.3)     1,597 (0.3) 
         
Recent Statin No   1064041 (82.8)    90,284 (83.3)   475,645 (78.2)    74,797 (74.0)   423,315 (90.6) 
  Yes   220,994 (17.2)    18,096 (16.7)   132,938 (21.8)    26,213 (26.0)    43,747 (9.4) 
         
Flu vaccine No   667,064 (51.9)    65,150 (60.1)   240,729 (39.6)    35,986 (35.6)   325,199 (69.6) 
  Yes   617,971 (48.1)    43,230 (39.9)   367,854 (60.4)    65,024 (64.4)   141,863 (30.4) 
         
Pneumococcal 
Vaccine No   1195495 (93.0)   101,794 (93.9)   557,468 (91.6)    91,049 (90.1)   445,184 (95.3) 
  Yes    89,540 (7.0)     6,586 (6.1)    51,115 (8.4)     9,961 (9.9)    21,878 (4.7) 
         
Exacerbation in last 
year No   1075873 (83.7)    93,180 (86.0)   486,952 (80.0)    64,309 (63.7)   431,432 (92.4) 
  Yes   209,162 (16.3)    15,200 (14.0)   121,631 (20.0)    36,701 (36.3)    35,630 (7.6) 
         
Immunosuppressed 
(combination 
algorithm) No   1260449 (98.1)   106,111 (97.9)   598,384 (98.3)    99,382 (98.4)   456,572 (97.8) 
  Yes    24,586 (1.9)     2,269 (2.1)    10,199 (1.7)     1,628 (1.6)    10,490 (2.2) 
         
GP consultation 
count Median (IQR) 6 (3-12) 6 (3-12) 7 (4-13) 9 (5-16) 5 (2-10) 
  Mean (SD) 9.26 (10.78) 9.22 (10.55) 10.21 (11.10) 12.77 (13.37) 7.28 (9.32) 
  Min, Max 0, 604 0, 286 0, 548 0, 604 0, 604 
         
Exacerbation Count Median (IQR) 0 (0-0) 0 (0-0) 0 (0-0) 0 (0-1) 0 (0-0) 
  Mean (SD) .296 (1.03) .24 (.95) .35 (1.09) .812 (1.71) .13 (.68) 
  Min, Max 0, 17 0, 16 0, 17 0, 17 0, 16 
Box 1: Prespecified hypothetical confounders 
● Age 
● Sex 
● Body Mass Index (BMI): Measurement of weight in the last decade 
● Indices of multiple deprivation (IMD): Quintiles from IMD 2019  
● Diagnosed hypertension 
● Heart disease: categorised as heart failure and other heart disease 
● Diabetes: categorised as controlled (HbA1c < 58 mmol/mol), uncontrolled (HbA1c 
≥ 58 mmol/mol) or HbA1c not measured measured within the last 12 months 
● Cancer 
● Immunosuppressive conditions: organ transplant, sickle cell anaemia and 
splenectomy 
● Chronic kidney disease: based on creatinine measurements within the last 12 
months or ever having a code for renal dialysis 
● Influenza vaccination status: recorded between 01Sep 2019 and 01 Mar 2020 
● Pneumococcal vaccination status: record in the five years prior to 01 Mar 2020 
● Statin use: recorded within four months prior to 1st of March 2020,  
● Exacerbation history: different methods used for asthma 31  and COPD population 
32with COPD models additionally adjusted for a history of asthma. 
 
Box 2: Research in Context  
Evidence before this study  
At the start of the global coronavirus outbreak, Inhaled Corticosteroids (ICS) were 
hypothesised to offer some protection against either infection with SARS-CoV-2 or against 
severe outcomes from COVID-19, such as acute respiratory distress syndrome (ARDS) 
and respiratory failure9, despite these medications being known to increase the risk of 
pneumonia and other respiratory tract infections17,33. The hypothesis was based at least in 
part on epidemiological data showing a low prevalence of chronic respiratory disease 
among Chinese COVID-19 patients2, although there was also some support of a potential 
protective effect from in-vitro studies12,13. Most recently, ICS exposure has been found to 
correlate with a lower expression of ACE2 and TMPRSS2, the entry receptors used by 
SARS-CoV-2, in sputum cells34. A recent systematic review evaluating whether 
administration of ICS was associated with clinical outcomes in COVID-19, SARS or MERS 
identified no relevant studies10.  
Added value of this study  
Our study was specifically designed to assess the role of pre-morbid ICS use in COVID-
19. We included two cohorts of participants: people with asthma, and people with COPD, 
both of whom have a possible indication for ICS. Neither analysis was strongly suggestive 
that regular ICS therapy for asthma or COPD has a clinically important causal effect on 
COVID-19 mortality in either direction. 
 
Our study has several key strengths: Firstly, it includes almost a million participants 
making it the largest contemporary study of ICS use to date. Secondly, we used active 
comparators and multiple sensitivity analyses to reduce and quantify the impact of 
possible unmeasured confounding. Finally, our analyses were pre-specified and we used 
open methods throughout the study with code and codelists available for examination and 
reuse.  
Implications of all the available evidence 
Evidence from our study and other research suggests there is neither a demonstrable 
benefit nor clear harm from ICS use against COVID-19 related mortality and therefore at 
present there is no evidence people should alter their ICS therapies during the pandemic. 
We also cannot recommend that ICS be used specifically to treat people with COVID-19 
outside of the context of clinical trials. Future observational research is likely to be subject 
to similar issues around unmeasured confounding, and evidence from RCTs will provide 
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